Rinkey Investments Reduces Holdings in Johnson & Johnson $JNJ

Key Points

• Rinkey Investments cut its Johnson & Johnson stake by 84% in the second quarter, selling 4,160 shares and retaining 794 shares valued at approximately $202,000.
• Johnson & Johnson reported better-than-expected quarterly results, with adjusted EPS of $2.90 and revenue of $25.31 billion, while revenue increased 6.6% year over year. The company maintained 2026 EPS guidance of $11.60–$11.75 and paid a quarterly dividend of $1.34 per share.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and average price target of $274.13, though valuation and the stock’s proximity to its 52-week high have raised concerns about limited near-term momentum.

Rinkey Investments lowered its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 84.0% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 794 shares of the company's stock after selling 4,160 shares during the quarter. Rinkey Investments' holdings in Johnson & Johnson were worth $202,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the stock. Blueline Advisors LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at $25,000. Semmax Financial Advisors Inc. boosted its stake in shares of Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock valued at $31,000 after acquiring an additional 72 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. increased its position in Johnson & Johnson by 946.7% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 157 shares of the company's stock worth $32,000 after purchasing an additional 142 shares in the last quarter. MidAtlantic Capital Management Inc. acquired a new position in Johnson & Johnson in the 4th quarter valued at about $37,000. Finally, Matrix Trust Co lifted its holdings in Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock valued at $38,000 after purchasing an additional 54 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Transactions at Johnson & Johnson

In other news, EVP Elizabeth Forminard sold 15,918 shares of the business's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. The trade was a 48.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is owned by company insiders.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received CE Marking in Europe for ACUVUE OASYS MAX 2-Week reusable contact lenses. The product uses the company’s proprietary MAX technologies and expands J&J Vision’s premium reusable lens portfolio, offering a potential source of incremental growth. Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
• Positive Sentiment: J&J secured Chinese approval for Icotyde, a once-daily oral treatment for moderate-to-severe plaque psoriasis. The therapy gives the company access to China’s large psoriasis market and could attract patients seeking an oral alternative to injectable treatments, although commercial results will take time to develop. Could Icotyde Become Johnson & Johnson’s Next Blockbuster in China?
• Neutral Sentiment: Coverage of J&J’s Wells Fargo healthcare conference highlighted its broader growth strategy, including continued emphasis on MedTech and cardiovascular care. The discussion reinforces the company’s long-term diversification but did not identify a major new financial catalyst. Johnson & Johnson Presents at Wells Fargo Healthcare Conference
• Neutral Sentiment: An investment article included JNJ as a potential dividend-income holding. This supports the stock’s defensive, income-oriented appeal but is not a new company announcement or direct earnings catalyst. The Portfolio You Need to Generate $500 a Month in Dividend Income
• Negative Sentiment: Analysts questioned whether JNJ’s rally is losing momentum. With shares trading near their 52-week high and at a premium earnings multiple, profit-taking and valuation concerns may be weighing on the stock despite the company’s solid operating outlook. JNJ Stock: Is the Rally Running Out of Steam?

Wall Street Analysts Forecast Growth

Several research firms have issued reports on JNJ. TD Cowen lifted their price target on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a "buy" rating in a report on Monday, July 13th. Guggenheim upped their price objective on shares of Johnson & Johnson from $270.00 to $287.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $284.00 to $294.00 and gave the stock an "overweight" rating in a research report on Thursday, July 16th. Wells Fargo & Company lifted their target price on shares of Johnson & Johnson from $272.00 to $282.00 and gave the stock an "overweight" rating in a research note on Monday, August 3rd. Finally, HSBC boosted their price target on Johnson & Johnson from $290.00 to $320.00 and gave the company a "buy" rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $274.13.

Johnson & Johnson Stock Down 0.3%

Shares of JNJ opened at $266.30 on Friday. Johnson & Johnson has a fifty-two week low of $173.33 and a fifty-two week high of $281.07. The company's fifty day moving average is $262.96 and its two-hundred day moving average is $245.79. The firm has a market cap of $641.76 billion, a PE ratio of 30.86, a price-to-earnings-growth ratio of 2.55 and a beta of 0.24. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business's revenue for the quarter was up 6.6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts forecast that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson's dividend payout ratio is currently 62.11%.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.